January 25, 2000
Taisho and Takeda Sign a Basic Agreement Regarding Joint Development Outside Japan
Taisho Pharmaceutical Co., Ltd. (President: Akira Uehara) and Takeda Chemical Industries, Ltd. (President: Kunio Takeda) today announced that they signed a basic agreement that they start the discussion for joint developments of Taisho's drug candidates in foreign countries.
The purpose of this basic agreement is to separately sign an agreement regarding each joint development when Takeda requests it based on Taisho's proposal of target drug candidate.
Target territories are North America and Europe. Taisho and Takeda will determine that they include Asian countries except Japan and other countries. Takeda will have priority to negotiate for exclusive marketing rights for target drug candidates in that territories. Other conditions will be attached in each agreement.
This collaboration enables Taisho and Takeda to provide more useful medicines in many countries. Consequently, both companies believe that this agreement will enable them to more fully contribute to medical treatment throughout the world.